Osterlund
Karolina Osterlund, Uppsala SE
Patent application number | Description | Published |
---|---|---|
20090215196 | Sequential Method - A method for determination of an analyte in an original liquid sample by performing an inhibition affinity assay in a microchannel structure of a microfluidic device. The main characteristic feature is the steps of: (i) providing the microfluidic device in a form where the microchannel structure comprises a reaction microcavity which a) an inlet end, and b) contains a solid phase with binding sites (BS) for an analyte or an analyte-related entity, (ii) providing a liquid sample (1) containing the analyte or the analyte-related entity within the microchannel structure at the inlet end of the reaction microcavity, and flowing sample (1) through the reaction microcavity under conditions such that the analyte or the analyte-related entity is captured by BS leaving a portion of BS unoccupied (free BS), (iii) providing a liquid sample (2) which contains an analytically detectable analogue of the analyte or of the analyte-related entity, and flowing sample (2) through said reaction microcavity to capture the analogue by free BS, and (iv) measuring the amount of analyte analogue captured in step (iii) and relating this amount to the amount of analyte in an original sample. | 08-27-2009 |
20110091904 | METHOD FOR DETERMINATION OF AFFINITY AND KINETIC CONSTANTS - The invention is related to a method for quantification of a first dissociation equilibrium constant K | 04-21-2011 |
20110195524 | SEMI-SEQUENTIAL ASSAY FOR DETECTION OF AN ANALYTE IN A SAMPLE - The invention is related to a method for detection of an analyte in a sample, wherein the method is a semi-sequential assay procedure. | 08-11-2011 |
Krister Osterlund, Molndal SE
Patent application number | Description | Published |
---|---|---|
20080312208 | Pyridine Analogues - The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y | 12-18-2008 |
20090042852 | Novel Pyridine Compounds - The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them. | 02-12-2009 |
Ragnar Osterlund, Ludvika SE
Patent application number | Description | Published |
---|---|---|
20110079755 | HIGH FIELD STRENGTH VARISTOR MATERIAL - The present invention relates to a varistor material for a surge arrester with target switching field strength ranging from 250 to 400 V/mm comprising ZnO forming a ZnO phase and Bi expressed as Bi | 04-07-2011 |
Russ Osterlund, Merrimack, NH US
Patent application number | Description | Published |
---|---|---|
20090319989 | MODIFICATION OF SOFTWARE AT RUNTIME - Disclosed are techniques for injecting one or more additional modules into a starting Windows process and ensuring that these modules are loaded and initialized at the earliest possible time by the Windows loader. The technique reuses the Windows loader by intercepting the normal loading of initial and subsequent module loads by the process at a single well-defined point in the loader. Methods for identifying and locating binary constructs using binary construct signatures are also disclosed. | 12-24-2009 |
20090322771 | Method for providing multiple users with private access to a computer - This disclosure describes a method for allowing multiple users to independently run graphical applications on a Windows computer at the same time by loading private instances of the graphics subsystem for each user at different virtual addresses within the kernel address space. | 12-31-2009 |
Torben Osterlund, Lund SE
Patent application number | Description | Published |
---|---|---|
20130040894 | INHIBITION OR ACTIVATION OF SERINE/THREONINE ULK3 KINASE ACTIVITY - The present invention relates to human serine/threonine kinase ULK3 and its ability to regulate GLI transcription factors; mediators of SHH signaling. This disclosure demonstrates that ULK3 enhances endogenous and over-expressed GLI1 and GLI2 transcriptional activity in cultured cells, and ULK3 alters subcellular localization of GLI1. According to this disclosure ULK3 is an autophosphorylated kinase and phosphorylates GLI proteins in vitro. A peptide sequence in GLI1 C-terminus that is phosphorylated by ULK3 is provided in this disclosure. ULK3 catalytical activity is shown to be crucial for its function in SHH pathway. This disclosure shows that serine/threonine kinase ULK3 is involved in the SHH pathway as a positive regulator of GLI proteins. Furthermore, a therapeutic method in SHH dependent human disorders is disclosed by pharmacological inhibition of ULK3 kinase activity. Identification of ULK3 substrate sequence in GLI1 allows the design of peptide-based modulators of its kinase activity. | 02-14-2013 |